Wang, Huitao Liu, Jianhe Fang, Kewei Ke, Changxing Jiang, Yongming Wang, Guang Yang, Tongxin Chen, Tao Shi, Xin
Published in
BMC Urology
BackgroundSecond-line treatment for urothelial carcinoma (UC) patients is used if progression or failure after platinum-based chemotherapy occurs or if patients are cisplatin-unfit. However, there is still no widely accepted treatment strategy. We aimed to analyze the effectiveness and safety of second-line treatment strategies for UC patients.Meth...
Alene, Muluneh Awoke, Tadesse Yenit, Melaku Kindie Tsegaye, Adino Tesfahun Yismaw, Leltework Yeshambel, Reta
Published in
BMC Research Notes
ObjectiveThis study was conducted to determine the rate of initial second-line ART regimen change and its predictors among adults living with HIV in Amhara region. A retrospective follow-up study was conducted between February, 2008 and April, 2016 at eight governmental hospitals of Amhara region. Person-times and Cox proportional hazard model were...
Alene, Muluneh Awoke, Tadesse Yenit, Melaku Kindie Tsegaye, Adino Tesfahun
Published in
BMC Infectious Diseases
BackgroundSecond-line Antiretroviral Therapy (ART) regimens are used when patients develop treatment failure for first-line drug regimens. It is costly unaffordable and it is not widely available for patients in resource limiting setting, there is a need to maximizing the duration of stay on second-line regimen. This study was conducted to estimate...
Schwartzberg, Lee Korytowsky, Beata Penrod, John R Zhang, Ying Le, T Kim Batenchuk, Cory Krug, Lee
Published in
Clinical lung cancer
The real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is unclear. We compared US patients who received second-line therapy for non-small-cell lung cancer (NSCLC) before and shortly after US Food and Drug Administration (FDA) approval of PD-L1 inhibitors. Patients in the Flatiron Health database (≥18 years; received first-line pl...
Shi, Yuankai Li, Jin Xu, Jianming Sun, Yan Wang, Liwei Cheng, Ying Liu, Wei Sun, Guoping Chen, Yigui Bai, Li
...
Published in
Cancer Communications
BackgroundThe 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational. In this study, we aimed to determine the clinical efficacy and safety of CMAB009 plus irinotecan c...
Carola, Candice Ghiringhelli, François Kim, Stefano André, Thierry Barlet, Juliette Bengrine-Lefevre, Leila Marijon, Hélène Garcia-Larnicol, Marie-Line Borg, Christophe Dainese, Linda
...
To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.
El Rassy, E. Assi, T. Bakouny, Z. Pavlidis, N. Kattan, J.
Published in
Clinical and Translational Oncology
Metastatic urothelial carcinoma of the bladder is a rarely curable disease. Patients receive systemic therapy with limited response rates and survival benefits. The rescue regimens of these patients who have failed first-line treatment had remained problematic until the recent advances. Several trials with novel regimens, including immune checkpoin...
Kim, Jung Hoon Lee, Sang-Cheol Oh, Sung Yong Song, Seo-Young Lee, Namsu Nam, Eun Mi Lee, Soonil Hwang, In Gyu Lee, Hyo Rak Lee, Kyu Taek
...
Published in
Cancer Communications
BackgroundCombination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second-line treatment after gemcitabine failure has not been tested prospectively. We investigated the feasibility and safet...
Jones, Keaton R. Lammert, Craig S.
Published in
Current Hepatology Reports
Purpose of ReviewAutoimmune hepatitis is a progressive T cell-dependent inflammatory process characterized by elevated autoantibodies, serum globulins, and interface hepatitis. Pharmacologic treatment focuses on achievement of complete biochemical remission. The goal of this paper is to describe the unique features that guide treatment in difficult...
Chrom, Pawel Kawecki, Maciej Stec, Rafal Bodnar, Lubomir Szczylik, Cezary Czarnecka, Anna M.
Published in
Medical Oncology
In order to facilitate long-term treatment decisions, we aimed to define biomarkers defining the probability of receiving second-line (SL) targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC) based on their characteristics present at first-line TT initiation. We analysed 152 consecutive mRCC patients treated and used multiv...
